SureTrader
Home > Boards > US OTC > Medical - Equipment >

Imagin Medical Inc. (IMEXF)

IMEXF RSS Feed
Add IMEXF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 2/20/2018 8:54:16 PM - Followers: 12 - Board type: Free - Posts Today: 0





 

 

Overview

 Imagin Medical is a medical imaging company
Imagin Medical will establish a new standard of care in the detection and removal of cancer using endoscopes by commercializing an advanced, proprietary and patented imaging technology
 Initially targeting bladder cancer 
 Thereafter expanding to all minimally invasive surgical (MIS) procedures where endoscopes are used
 

Benefits of Minimally Invasive Surgery (MIS)

• Performed using tiny holes or incisions (less muscle cut)
• Reduced pain, smaller / no scarring
• Quicker recovery, shorter hospital stay, less expensive
• Minimally invasive surgeries performed using endoscopes














 


Endoscopic Primer

• Endoscopic means “to look inside”
• Endoscope – a medical device with attached light used to look inside organs
• Endoscopy performed when other tools, such as an MRI, X-ray, or CT scan, are inappropriate
• Endoscopies commonly performed to diagnose cancer, take tissue samples for biopsies, and to remove cancer
• Different medical specialties use different types of endoscopes
• Cystoscopes, Bronchoscopes, Gastroscopes, Laparoscopes
   










 

Endoscopic Market
 
 $46B growing global endoscopy market
 $1B is spent annually in US alone on bladder cancer surveillance
 Bladder cancer is 3rd most common in men and 6th most common in US overall with recurrence rate of 40 – 70% making it the most expensive cancer to treat over the lifetime of a patient
 4 million estimated urology endoscopy procedures performed each year targeting bladder cancer
 Imagin’s disruptive imaging technology squarely addresses limitations in:
• Endoscopies targeting bladder cancer (cystoscopies)
• Endoscopies targeting many other cancers


 


 

Endoscope Limitations - White Light

• Current endoscopes use “white light” (or visible light) that has been the gold standard for decades
• Highly effective for detecting protruding cancerous tumors
• Limitations of white light:
• Tumors that are flat may look the same as normal tissue
• Not effective in visualizing the edges of the tumor
• Inability to illuminate tumors beneath skin surface


 

Endoscope Limitations - Blue Light

• Blue light cystoscopes (white light with blue filter) used with contrasting agents induce fluorescence and improve ability to detect flat cancers and visualize edges
• Drawbacks of existing blue light technology:
• Requires one hour for the agent to be absorbed by bladder
• Surgeon must manually “switch” between white light and blue light to see tumor area
• Repeated usage of imaging agent causes adverse side-effects (FDA limits use of contrast agents to one-time use per patient)
 

 
Disruptive Technology - Endoscopes with i/Blue Imaging System

• Significantly reduced prep time with bladder absorption in less than 15 minutes vs. one hour
• Optics 100,000 X more sensitive
• Simultaneous acquisition of differing images
• No switching back and forth
• Blends the white light and fluorescence images into one
• Enables the surgeon to better visualize and resect the cancer
• This advancement makes i/Blue technology practical, not only for the O.R. but also potentially for the physicians’ office
• Adapts seamlessly to most types of endoscopes on the market
 
Future Development - i/Vision Imaging System

• Incorporates multiple illumination sources in one system
• Accommodates the most commonly used fluorescing contrast agents, i.e., such as those based on the emission of Protoporphyrin IX (PpIX) and Indocyanine green (ICG)
• This instrument enables expansion into multiple endoscopic procedures such as laparoscopic (general and gynecology), colorectal, thoracic and gastroenterology procedures related to cancer and non-cancerous conditions
• Like i/Blue, blends two images into one, adapts to most endoscopes, and orders of magnitude more sensitive
 
Future Development - i/Red Imaging System

• Requires no contrasting agents - uses the fluorescence produced by the body and tumor itself
• Contrast between normal and cancer tissue is potentially related to difference in porphyrin content within the cells
• Dramatically expands the market to endoscopic procedures where imaging agents cannot be practically administered
• Like i/Blue, blends two images into one, adapts to most endoscopes, orders of magnitude more sensitive
 
Intellectual Property

• Underpinning company’s technology are three issued patents and two pending patent applications on technology related to near-infrared spectroscopic imaging for cancer and other medical applications obtained, under exclusive license, from Lawrence Livermore National Security, LLC
• Aim of licensing agreement is to commercialize the technology invented by Dr. Stavros Demos, a key advisor to the company


 
Product Development Roadmap


 
Why Invest in Imagin Medical?

• Key investment risks removed, high investment return potential
• Disruptive cutting edge imaging technology will dramatically reduce bladder cancer recurrence rates addressing $1B growing global market
• Limited R&D risks as concept is proven – this is an execution play
• Experienced medical device management team that has done it before
• Management in medical device field for over 30 years
• Worked together in previous companies
• High-margin product with strong clinical and economic advantages
• Commercial launch expected in 2018 with positive operating cash flows
• Strong acquisition market
• Most medical device companies grow by acquisition, not organically
• Company expected to have significant value with multiple liquidity options
 

 
Number of Shares Outstanding as at August 31, 2017:                50,068,739
 
Shares Subject to Resale Restrictions    
1) Shares subject to escrow (1,725,000 released every 6 months - Feb 9 & Aug 9) 5,175,000  
2) Performance shares 5,000,000  
Total Shares Subject to Resale Restrictions   10,175,000
Total Tradeable Float   39,893,739
Total Shares Outstanding   50,068,739

Number of Warrants Outstanding as at August 31, 2017:             25,005,064
 
Warrants Outstanding    
Feb 2016 Private Placement Strike @ 0.35 - expire Feb 9, 2018 7,007,413
Q4/2016 PP - Tranche 1 Strike @ 0.12 / 0.16 - expire Oct 20, 2018 5,111,300
Q4/2016 PP - Tranche 2 Strike @ 0.12 / 0.16 - expire Dec 9, 2018 3,980,565
Warrants from BSS acquisition Strike @ 0.15 - expire Feb 9, 2019 8,905,786
Total Warrants Outstanding   25,005,064

Number of Options Outstanding as at August 31, 2017:                3,350,000
 
 Management Options Outstanding    
Tranche 1 Strike @ 0.15 3,350,000
Total Options Outstanding   3,350,000
 
Various Company Links

Company Web Site
Corporate Presentation (10/2/2017)

CSE Web Site for Imagin Medical
SEDAR Web Site for Imagin Medical

Listing Statement CSE - February 16, 2016

Share Issuance - February 9, 2016
Share Issuance - August 22, 2016
Share Issuance - October 21, 2016
Share Issuance - December 13, 2016
Convertible Debt Issuance - March 3, 2017
Share Issuance - October 4, 2017

Option Grant - June 30, 2016
Option Grant - December 19, 2016
Option Grant - April 10, 2017

Information Circular - October 31, 2016

Monthly CSE Filings (CSE Form 7)
 
  2016 2017
January N/A Link
February Link Link
March Link Link
April Link Link
May Link Link
June Link Link
July Link Link
August Link Link
September Link  
October Link  
November Link  
December Link  

Financial Statements (FS) & Management Discussion and Analyses (MD&A)
 
      2015 2016 2017
Q2 Quarter Ended March 31 FS   Link Link
MD&A   Link Link
Q3 Quarter Ended June 30 FS   Link Link
MD&A   Link Link
Q4 Quarter Ended September 30 FS Link Link  
MD&A Link Link  
Q1 Quarter Ended December 31 FS Link Link  
MD&A Link Link  

 

 
SureTrader
IMEXF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#550   Dilution is par for the course for any AMG 02/20/18 08:54:16 PM
#549   Better not mention dilution or AMG will go ballistic. MSU 02/20/18 10:40:26 AM
#548   They already have diluted a large amount and 7Card 02/19/18 11:51:16 PM
#547   New poster here. I own IMEXF as IMeasy 02/19/18 03:27:05 PM
#546   Sounds like a paid poster to me. MSU 02/18/18 01:38:40 PM
#545   I won’t hold my breath! MSU 02/17/18 12:41:24 PM
#544   I'll Get Back To You Shortly. AMG 02/17/18 11:46:40 AM
#543   Riddle me this? What is the next milestone here MSU 02/17/18 11:21:09 AM
#542   Proceed on MSU 02/17/18 11:18:25 AM
#541   LOL. MSU are you here to create a AMG 02/17/18 11:16:49 AM
#539   That's what penny land is. You are buying SO75 02/17/18 11:05:26 AM
#538   How about potential revenue? MSU 02/17/18 11:02:39 AM
#536   Revenue means nothing on the CSE. SO75 02/17/18 08:40:47 AM
#535   Oh I thought success was reflected in Revenue. But MSU 02/17/18 03:27:17 AM
#534   IME dosnt't need revenue to pop. See BLO SO75 02/16/18 02:23:45 PM
#533   Thank you I along with others will continue MSU 02/16/18 11:20:27 AM
#532   Some things are Common Sense 101. Which includes AMG 02/16/18 11:16:46 AM
#531   What is bewildering to me is that when MSU 02/16/18 11:10:40 AM
#530   American Urological Association (AUA) Honors Imagin Medical Scientific Advisor AMG 02/15/18 02:14:42 PM
#529   Interesting but not surprising how folks can be AMG 02/15/18 11:20:45 AM
#528   I agree, I read a lot about their dds003 02/14/18 03:33:30 PM
#527   Where is all of that selling that someone MSU 02/14/18 12:50:53 PM
#526   These biotech companies are a dime a dozen, MSU 02/14/18 12:33:29 PM
#525   Could be years away. Look out dilution here we come! MSU 02/14/18 12:28:54 PM
#524   Yes, from what they said in their release 7Card 02/13/18 02:57:51 PM
#523   All were selling today, maybe I have made MSU 02/12/18 09:33:06 PM
#522   Is the NO News release hiding something. Nonperformance maybe? 7Card 02/12/18 02:39:47 PM
#521   Load up now, when the next PR on MSU 02/12/18 01:08:02 PM
#520   I find the slump of share price falconer66a 02/12/18 11:08:27 AM
#519   I agree with your summary. Imagin has 7Card 02/10/18 11:32:04 AM
#518   No new info, but a good summary of falconer66a 02/09/18 02:06:36 PM
#517   New article on IMEXF I found. A really Crytek89 02/09/18 09:55:41 AM
#516   University of Rochester Initial Research Study Patients Completed University SO75 02/07/18 09:56:34 AM
#515   No worries. Look there may be some selling next MSU 01/31/18 04:41:15 PM
#514   Ya but im not happy about the new PP. SO75 01/31/18 04:33:04 PM
#513   The ride will be very smooth. MSU 01/31/18 04:32:24 PM
#512   Been riding this company since Dec 2016. It's SO75 01/30/18 11:04:11 AM
#511   You are a smart young man, it would MSU 01/30/18 10:57:43 AM
#510   Profit is profit...but anyone who sells now is SO75 01/30/18 10:30:29 AM
#509   Almost 40 million shares in the PP bought Neverending 01/30/18 09:59:08 AM
#508   Or buy on the dilution..your call SO75 01/29/18 11:10:40 PM
#507   Oh no, now we must sell, before they MSU 01/29/18 09:27:21 PM
#506   When this was written there was 2 more SO75 01/29/18 05:13:36 PM
#505   $3 to $4 valuation is too low. When 7Card 01/29/18 02:04:44 PM
#504   http://aheadoftheherd.com/1Articles/Other/Imagin-Valuation-Report.pdf MSU 01/28/18 08:27:57 PM
#503   Where Will This Go? falconer66a 01/27/18 03:56:15 PM
#502   $3 to $4 valuation. Article attached. 7Card 01/25/18 12:34:39 PM
#501   When the Momo players arrive, yeah with this MSU 01/23/18 09:31:50 PM
#500   There should be some milestones that will pop Neverending 01/22/18 01:32:52 PM
#499   I still think this could be at .75 soon. MSU 01/22/18 12:42:14 PM
PostSubject